Document is current
Any future updates will be listed below
-
Authors
Secher, Anna https://orcid.org/0000-0002-6276-5389
Lutz, Thomas A. https://orcid.org/0000-0002-5056-8548
Raun, Kirsten https://orcid.org/0000-0001-7605-8215
- License Information
-
More Information
Article History
Received: 16 July 2025
Accepted: 13 January 2026
First Online: 18 February 2026
Competing interests
: A.S. and K.R. are employees of Novo Nordisk A/S, which is developing amylin-based drugs for the treatment of metabolic diseases. K.R. is listed as inventor on the patent covering CagriSema, a fixed-dose combination of an amylin analogue and a GLP1R analogue. T.A.L. has research collaborations with Novo Nordisk A/S, had a collaboration with Structure Therapeutics and has consulted for AbbVie, AstraZeneca, Eli Lilly, Roche and Zealand Pharma.
